Conjugation of Y. pestis F1-antigen to gold nanoparticles improves immunogenicity.

The efficacy of 15 nm gold nanoparticles (AuNP) coated with Yersinia pestis F1-antigen, as an immunogen in mice, has been assessed. The nanoparticles were decorated with F1-antigen using N-hydroxysuccinimide and N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride coupling chemistry. Mice given AuNP-F1 in alhydrogel generated the greatest IgG antibody response to F1-antigen when compared with mice given AuNP-F1 in PBS or given unconjugated F1-antigen in PBS or alhydrogel. Compared with unconjugated F1-antigen, the IgG2a response was enhanced in mice dosed with AuNP-F1 in PBS (p<0.05) but not in mice immunised with AuNP-F1 in alhydrogel. All treatment groups developed a memory response to F1-antigen, the polarity of which was inflenced by formulation in alhydrogel. The sera raised against F1-antigen coupled to AuNPs was able to competitively bind to rF1-antigen, displacing protective macaque sera.

[1]  M. Akashi,et al.  Modulation of innate and adaptive immunity by biodegradable nanoparticles. , 2009, Immunology letters.

[2]  W. Mark Saltzman,et al.  Synthetic DNA delivery systems , 2000, Nature Biotechnology.

[3]  S. Davis,et al.  Controlled release microparticles for vaccine development. , 1991, Vaccine.

[4]  Sihai Chen,et al.  Synthesis and Characterization of Carboxylate-Modified Gold Nanoparticle Powders Dispersible in Water , 1999 .

[5]  A. Simpson,et al.  Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague. , 2011, Vaccine.

[6]  Lin Zeng,et al.  The use of a gold nanoparticle-based adjuvant to improve the therapeutic efficacy of hNgR-Fc protein immunization in spinal cord-injured rats. , 2011, Biomaterials.

[7]  T. Schwan,et al.  Recombinant capsular antigen (fraction 1) from Yersinia pestis induces a protective antibody response in BALB/c mice. , 1990, The American journal of tropical medicine and hygiene.

[8]  L. Rome,et al.  Nanobiology: particles slip cell security. , 2008, Nature materials.

[9]  C. Wheeler,et al.  Priming of Human Papillomavirus Type 11-Specific Humoral and Cellular Immune Responses in College-Aged Women with a Virus-Like Particle Vaccine , 2002, Journal of Virology.

[10]  Brigitte Colau,et al.  Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. , 2006, Vaccine.

[11]  M. Akashi,et al.  Targeting of Antigen to Dendritic Cells with Poly(γ-Glutamic Acid) Nanoparticles Induces Antigen-Specific Humoral and Cellular Immunity1 , 2007, The Journal of Immunology.

[12]  Virander S. Chauhan,et al.  Induction of humoral immune response against PfMSP-1(19) and PvMSP-1(19) using gold nanoparticles along with alum. , 2011, Vaccine.

[13]  Shaker A Mousa,et al.  Emerging nanopharmaceuticals. , 2008, Nanomedicine : nanotechnology, biology, and medicine.

[14]  B Ruozi,et al.  PLA/PLGA nanoparticles for sustained release of docetaxel. , 2006, International journal of pharmaceutics.

[15]  O. Schneewind,et al.  Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines. , 2011, Vaccine.

[16]  R. Titball,et al.  Expression of the Yersinia pestis capsular antigen (F1 antigen) on the surface of an aroA mutant of Salmonella typhimurium induces high levels of protection against plague , 1997, Infection and immunity.

[17]  H. Flick-Smith,et al.  Human Immune Response to a Plague Vaccine Comprising Recombinant F1 and V Antigens , 2005, Infection and Immunity.

[18]  Eric Stern,et al.  Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. , 2012, Biomaterials.

[19]  S. Welkos,et al.  Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge , 1996, Infection and immunity.

[20]  C. Soto,et al.  Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice. , 2010, Biochemical and biophysical research communications.

[21]  Deborah H Fuller,et al.  Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. , 2006, Methods.

[22]  Stephan Barcikowski,et al.  Nonendosomal cellular uptake of ligand‐free, positively charged gold nanoparticles , 2010, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[23]  R. Perry,et al.  Yersinia pestis--etiologic agent of plague , 1997, Clinical microbiology reviews.

[24]  Akiko Yamamoto,et al.  Cytotoxicity evaluation of ceramic particles of different sizes and shapes. , 2004, Journal of biomedical materials research. Part A.

[25]  G. Altavilla,et al.  Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration. , 2009, Vaccine.

[26]  R. Titball,et al.  Local and systemic immune response to a microencapsulated sub-unit vaccine for plague. , 1996, Vaccine.

[27]  W. Blackwelder,et al.  Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V). , 2010, Vaccine.

[28]  Ana Barešić,et al.  E2 allele of the Apolipoprotein E gene polymorphism is predictive for obesity status in Roma minority population of Croatia , 2011, Lipids in Health and Disease.

[29]  H. Flick-Smith,et al.  Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates. , 2007, Microbial pathogenesis.

[30]  Hui Xu,et al.  Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. , 2002, International journal of pharmaceutics.

[31]  Anil Mahapatro,et al.  Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines , 2011, Journal of nanobiotechnology.

[32]  R. Titball,et al.  An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model , 1999, Clinical and experimental immunology.

[33]  T. Park,et al.  Determinants of Release Rate of Tetanus Vaccine from Polyester Microspheres , 1993, Pharmaceutical Research.

[34]  S. Franzen,et al.  Probing BSA binding to citrate-coated gold nanoparticles and surfaces. , 2005, Langmuir : the ACS journal of surfaces and colloids.

[35]  C. Kao,et al.  Effects of soil pH, temperature and water content on the growth ofBurkholderia pseudomallei , 2008, Folia Microbiologica.

[36]  M. Sastry,et al.  Chitosan Reduced Gold Nanoparticles as Novel Carriers for Transmucosal Delivery of Insulin , 2007, Pharmaceutical Research.

[37]  M. M. Mady,et al.  Liver uptake of gold nanoparticles after intraperitoneal administration in vivo: A fluorescence study , 2011, Lipids in Health and Disease.

[38]  R. Titball,et al.  A new improved sub-unit vaccine for plague: the basis of protection. , 1995, FEMS immunology and medical microbiology.

[39]  S. Welkos,et al.  Advanced Development of the rF1V and rBV A/B Vaccines: Progress and Challenges , 2011, Advances in preventive medicine.

[40]  Sung Ju Cho,et al.  Unmodified cadmium telluride quantum dots induce reactive oxygen species formation leading to multiple organelle damage and cell death. , 2005, Chemistry & biology.

[41]  Yao-Ching Hung,et al.  Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide , 2010, Nanotechnology.

[42]  M. J. Pearce,et al.  Macromolecular organisation of recombinant Yersinia pestis F1 antigen and the effect of structure on immunogenicity. , 1998, FEMS immunology and medical microbiology.

[43]  R. Titball,et al.  A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague. , 1997, Vaccine.

[44]  J. Hillier,et al.  A study of the nucleation and growth processes in the synthesis of colloidal gold , 1951 .

[45]  Jimmy C. Yu,et al.  Effects of Cu2O nanoparticle and CuCl2 on zebrafish larvae and a liver cell-line. , 2011, Aquatic toxicology.

[46]  R. Gupta,et al.  Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. , 1994, Vaccine.

[47]  Arezou A Ghazani,et al.  Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. , 2006, Nano letters.

[48]  C. Murphy,et al.  Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. , 2005, Small.

[49]  Terrorism from a public health perspective. , 2002, The American journal of the medical sciences.

[50]  W. Mark Saltzman,et al.  Nanosystems for simultaneous imaging and drug delivery to T cells , 2007, The AAPS Journal.